Contract Pharma Staff10.01.20
Bioclinica, an integrated solutions provider of clinical life science and technology expertise, has announced a new, unified Medical and Scientific Affairs organization led by Michael O'Neal, MD, in an expanded role as chief medical officer.
The Medical and Scientific Affairs team will be aligned by therapeutic area with individual practice leaders for each area. With O'Neal's oversight, Julie Cole, MD, will lead the Oncology team directly in her role as VP of oncology, medical imaging.
The practice leaders will be supported by a shared services organization leading improvement initiatives across therapeutic areas, centered around integration, communication, and process efficiency. These changes will promote a more uniform operational approach to medical imaging.
"Transitioning to this new operating design would not be possible without the collective capabilities of our medical and scientific affairs teams," said Euan Menzies, chairman and CEO. "This will allow us to continue to provide superior support and service for all clients while also looking to drive improved utilization of technology across all aspects of our work."
Team Members
Rejoining Bioclinica is Klaus Noever, MD, based in Munich, Germany. Noever will support the Medical and Scientific Affairs team in Europe.
Other recent medical leadership additions to the team include:
Jeffrey DiPaolo, MD, neuroradiologist
Robert Ludwig, MD, radiologist
Elizabeth Greenstein, MD, Nuclear Medicine and PET radiologist
"We are fortunate to have such strength in our key therapeutic areas," said O'Neal. "We have multiple critical touchpoints across all aspects of medical imaging, and with our clients, CROs, and many sites. This will allow greater focus on Oncology and room for expansion of current capabilities in Neuroscience, Musculoskeletal, Cardiac Services, as well as Gastrointestinal and Liver."
The Medical and Scientific Affairs team will be aligned by therapeutic area with individual practice leaders for each area. With O'Neal's oversight, Julie Cole, MD, will lead the Oncology team directly in her role as VP of oncology, medical imaging.
The practice leaders will be supported by a shared services organization leading improvement initiatives across therapeutic areas, centered around integration, communication, and process efficiency. These changes will promote a more uniform operational approach to medical imaging.
"Transitioning to this new operating design would not be possible without the collective capabilities of our medical and scientific affairs teams," said Euan Menzies, chairman and CEO. "This will allow us to continue to provide superior support and service for all clients while also looking to drive improved utilization of technology across all aspects of our work."
Team Members
Rejoining Bioclinica is Klaus Noever, MD, based in Munich, Germany. Noever will support the Medical and Scientific Affairs team in Europe.
Other recent medical leadership additions to the team include:
Jeffrey DiPaolo, MD, neuroradiologist
Robert Ludwig, MD, radiologist
Elizabeth Greenstein, MD, Nuclear Medicine and PET radiologist
"We are fortunate to have such strength in our key therapeutic areas," said O'Neal. "We have multiple critical touchpoints across all aspects of medical imaging, and with our clients, CROs, and many sites. This will allow greater focus on Oncology and room for expansion of current capabilities in Neuroscience, Musculoskeletal, Cardiac Services, as well as Gastrointestinal and Liver."